Live Breaking Biotech News and Articles

Biotech News Journal

Subscribe to Biotech News Journal: eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Biotech News Journal: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn


Biotech Authors: Greg Wind

Related Topics: CEOs in Technology, Fitness Journal, Biotech News Journal, FDA News, Government News, Sarbanes Oxley on Ulitzer

News Feed Item

Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, August 29, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.

--
Mallinckrodt plc Research Reports
On August 25, 2014, Mallinckrodt plc (Mallinckrodt) reported that Mark Trudeau, President and CEO, will present on behalf of the Company at the Morgan Stanley Global Healthcare Conference in New York on September 8, 2014 in a session scheduled to begin at 9:20 a.m. ET. A replay of the event will be available on Mallinckrodt's website. The full research reports on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/Aug-29-2014/MNK/report.pdf

--
Vertex Pharmaceuticals Incorporated Research Reports
On August 26, 2014, the stock of Vertex Pharmaceuticals Incorporated (Vertex Pharmaceuticals) gained 2.05% to end the trading session at $93.64. After opening at $90.89, the stock fluctuated in the range of $90.89 - $94.50. Over the last one month, Vertex Pharmaceuticals' stock has declined by 2.20%, compared to the S&P 500, which gained 1.10% during the same period. The full research reports on Vertex Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Aug-29-2014/VRTX/report.pdf

--
Kite Pharma, Inc. Research Reports
On August 26, 2014, Kite Pharma, Inc. (Kite) announced that it will participate in the Citi's 9th Annual Biotech Conference on September 3, 2014, at 6:00 p.m. ET at the Mandarin Oriental in Boston. The Company added that Arie Belldegrun, M.D., FACS, President and CEO, will discuss the Company's development efforts on a panel titled "How CAR-T Cell Therapies are Shaping Oncology's Future". The full research reports on Kite are available to download free of charge at:

http://www.analystsreview.com/Aug-29-2014/KITE/report.pdf

--
Bristol-Myers Squibb Company Research Reports
On August 21, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb) along with Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Eliquis for the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the decrease in the risk of recurring DVT and PE following initial therapy. According to the Company, the approval for Eliquis was based on data from the global AMPLIFY and AMPLIFY-EXT studies. In the AMPLIFY study, Eliquis established superiority in the primary safety endpoint of major bleeding versus standard of care, and for the secondary safety endpoint in the study, the event rates for clinically relevant non major bleeding (CRNM) were less in Eliquis-treated patients as compared to standard of care-treated patients. The full research reports on Bristol-Myers Squibb are available to download free of charge at:

http://www.analystsreview.com/Aug-29-2014/BMY/report.pdf

--
Arrowhead Research Corp. Research Reports
On August 12, 2014, Arrowhead Research Corp. (Arrowhead) announced its Q3 FY 2014 financial results (period ended June 30, 2014) and also issued an update on the Phase 2a study of ARC-520, its RNAi-based candidate for the treatment of chronic hepatitis B infection. The revenues of the Company remained flat at $43,750 as compared to Q3 FY 2014. The net loss attributable to the Company widened to $11.6 million as compared to $6.1 million in Q3 FY 2014. In context of Phase 2a study of ARC-520, the Company informed that it has completed dosing of 1 mg/kg and 2 mg/kg dose cohorts, and has received IRB and DSMB approvals to proceed and began enrolling an additional dose cohort at 3 mg/kg in the Phase 2a patient study. The full research reports on Arrowhead are available to download free of charge at:

http://www.analystsreview.com/Aug-29-2014/ARWR/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

 

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.